Abstract YO34
Case summary
Background
Alteration in Urinary phosphate levels has been considered to be a paraneoplastic syndrome. This case report sheds light on a rare endocrinological cause of limb weakness.
Case details
A 31 year old female, a known case of pleomorphic leiomyosarcoma post surgery, post adjuvant chemotherapy with recently diagnosed parenchymal and pleural deposits presented with weakness in legs since the past 3 days, abnormal movements involving both the arms since the past 1 day and altered sensorium since the past 2 days. There was no history of symptoms of raised intracranial tension or metastatic spinal cord compression. Examination revealed reduced power in both the upper and lower limbs with downgoing flexors. Further investigation revealed reduced levels of serum phosphate, serum calcium and transaminiitis. Based upon recent reports available with the patient, vitamin D levels were found to be low whereas Intact PTH was found to be normal. A diagnosis of tumor induced osteomalacia versus Pazopanib induced fanconi’s syndrome was considered. She was started on oral phosphate supplements and vitamin D.
Conclusion
Tumor induced osteomalacia needs to be recognized as a reversible causes of quadriparesis in the advanced cancer population with mesenchymal tumours. The diagnosis was made in the Palliative medicine ward in the absence of 24 hour urinary phosphate levels or serum FGF levels.
Laboratory parameters | 24-01-2019 | 25-01-2019 |
Total Calcium | 1.9 | 1.5 |
Serum Urea | 20 | 17 |
Serum Creatinine | 0.5 | 0.4 |
Serum Uric Acid | 3.5 | |
Serum Sodium | 134 | |
Serum Potassium | 3.03 | |
Serum Chloride | 105.8 | |
Serum PTH | 71.90 | |
Serum Vitamin D3 | 12.26 | |
Total leucocyte count | 1070 | 900 |
Serum Haemoglobin | 13.2 | 9.7 |
QTc interval (corrected) | ||
Bazette's | 0.5 | 0.47 |
Frederica's | 0.49 | 0.46 |
Framingham | 0.52 | 0.46 |
Hodges | 0.52 | 0.45 |
Clinical trial identification
Editorial acknowledgement
Resources from the same session
258P - Assessment of sexual health in patients treated for ovarian cancer
Presenter: Renu Madan
Session: Poster display session
Resources:
Abstract
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract